Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05641753 · ClinicalTrials.gov registry record · Phase 4
Cholesterol Lowering and Residual Risk in Diabetes, Type 1
A Phase 4 study of Type 1 Diabetes, sponsored by NYU Langone Health.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 125
- Enrollment target
- 4
- Study locations
NCT05641753 is a Phase 4 study of Type 1 Diabetes that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 125 participants, below the 824-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (85% lower). The trial reports 4 study locations across 1 state.
The verdict
NCT05641753, a Phase 4 study of Type 1 Diabetes, is actively recruiting participants, sponsored by NYU Langone Health.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 125 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a prospective, interventional, cohort study, meaning that researchers will follow and observe a group of enrolled study participants over a period of time (one to two months) to gather information and record any developments of the outcomes in question. This study will recruit 125 participants with Type 1 Diabetes (T1D) to: 1. Analyze the effect of reducing the cholesterol levels in the blood on platelet function. (Platelets are small cells in the blood which help form blood clots to slow or stop bleeding and to help wounds heal 2. Analyze the effect of reducing the cholesterol levels in the blood on While Blood Cell (WBC) gene expression, (White Blood Cells are part of the body's immune system which help the body fight infection and other diseases) and 3. Analyze the effect of reducing the cholesterol levels in the blood on vascular or blood vessel function.
Conditions Studied
Interventions
- DRUG 18F-FDG
- DRUG Evolocumab Cartridge
- DRUG Atorvastatin Calcium Tablets
- DRUG Ezetimibe Tablets
- DEVICE Angiocatheter 20IV
Study Locations (4)
New York
- New York VA Hospital - New York
- NYC Health + Hospitals/Bellevue - New York
- NYU Langone Health - New York
- Mount Sinai School of Medicine - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2022-12-06 |
| Est. Completion | 2027-07-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05641753
The ClinicalTrials.gov registry entry for NCT05641753 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 824-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (85% lower). The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 1 Diabetes appearing as the primary indexed condition, and to 5 interventions - of which 18F-FDG is the first listed.
NCT05641753 reports 4 study locations spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT05641753 about?
NCT05641753 is a clinical study titled "Cholesterol Lowering and Residual Risk in Diabetes, Type 1". This is a prospective, interventional, cohort study, meaning that researchers will follow and observe a group of enrolled study participants over a period of time (one to two months) to gather information and record any developments of the outcomes in question. This study will recruit 125 participa...
What is the current status of trial NCT05641753?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 125 participants. The study started on 2022-12-06. Estimated completion is 2027-07-31.
What conditions does trial NCT05641753 study?
This clinical trial studies the following conditions: Type 1 Diabetes.
What interventions are being tested in trial NCT05641753?
The interventions under investigation include: 18F-FDG (DRUG), Evolocumab Cartridge (DRUG), Atorvastatin Calcium Tablets (DRUG), Ezetimibe Tablets (DRUG), Angiocatheter 20IV (DEVICE).
Who is sponsoring clinical trial NCT05641753?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05641753 being conducted?
This trial has 4 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Extended Bolus for Meals in a Closed-loop System
RECRUITING · Phase 4
-
Comparison of Glargine to Degludec Insulin Transition With or Without a Bridging Glargine Dose
COMPLETED · Phase 4
-
Lunch Time Insulin Injection by School Nurse for Poorly Controlled Diabetes
COMPLETED · Phase 4
-
Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 Diabetes
COMPLETED · Phase 4
-
Intravenous Insulin vs Subcutaneous Insulin Infusion in Intrapartum Management of Type 1 Diabetes Mellitus
COMPLETED · Phase 4
-
A Pilot Study to Assess the Glucose Lowering Effect of Metformin and Sitagliptin in Adolescents With Type 1 Diabetes
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.